New oral anticoagulants in the prevention of embolic complications in patients with atrial fibrillation. Polish Cardiac Society, Polish Neurological Society and Working Group on Haemostasis of the Polish Society of Haematologists and Transfusiologists consensus statement;Zastosowanie nowych doustnych leków przeciwkrzepliwych w prewencji powikłań zatorowych u chorych z migotaniem przedsionków. Stanowisko grupy ekspertów Polskiego Towarzystwa Kardiologicznego, Polskiego Towarzystwa Neurologicznego i Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów

Kardiologia Polska

Volumn 70, Issue 9, 2012, Pages 979-988

  Pruszczyk, Piotr ^a   Stȩpińska, Janina ^b   Banasiak, Waldemar ^c   Członkowska, Anna ^a,d   Opolski, Grzegorz ^e   Niewada, Maciej ^a,d   Ponikowski, Piotr ^c,f   Tendera, Michał ^g   Windyga, Jerzy ^h  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c Wroclaw Medical University Katedra i Klinika Kardiologii   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^e WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CONSENSUS; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; POLAND; REVIEW;

EID: 84866696908     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Heeringa J, Conway DS, van der Kuip DA et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: The rotterdam study 1990-1999. J Thromb Haemost, 2006; 4: 1944-1949
2. Knecht S, Oelschlager C, Duning T et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J, 2008; 29: 2125-2132
3. Stewart S, Hart CL, Hole DJ et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the renfrew/paisley study. Am J Med, 2002; 113: 359-364.
4. Stewart S, MacIntyre K, Chalmers JW et al. Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in scotland, 1986-1995. Int J Cardiol. 2002;82:229-236
5. Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke, 2005; 36: 1115-1119
6. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: Analysis of randomized clinical trials. Stroke, 2002; 33: 2722-2727.
7. Matute MC, Guillan M, Garcia-Caldentey J et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost, 2011; 106: 178-179.
8. Carolei A, Marini C, Di Napoli M et al. High stroke incidence in the prospective community-based l'aquila registry (1994-1998). First year's results. Stroke, 1997; 28: 2500-2506.
9. Lip GY, Beevers DG, Singh SP et al. Abc of atrial fibrillation. Aetiology, pathophysiology, and clinical features. BMJ, 1995; 311: 1425-1428
10. Saxena R, Lewis S, Berge E et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the international stroke trial. Stroke, 2001; 32: 2333-2337.
11. Niewada M, Skowronska M, Ryglewicz D et al. Acute ischemic stroke care and outcome in centers participating in the polish national stroke prevention and treatment registry. Stroke, 2006; 37: 1837-1843.
12. Hannon N, Sheehan O, Kelly L et al. Stroke associated with atrial fibrillation:incidence and early outcomes in the north dublin population stroke study. Cerebrovasc Dis, 2010; 29: 43-49.
13. Mizrahi EH, Waitzman A, Arad M et al. Atrial fibrillation predicts cognitive impairment in patients with ischemic stroke. Am J Alzheimers Dis Other Demen, 2012 [in press].
14. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146: 857-867.
15. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 2003; 290: 2685-2692.
16. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817
17. Baker WL, Cios DA, Sander SD et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the united states. J Manag Care Pharm, 2009; 15: 244-252.
18. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med, 1994; 120: 897-902.
19. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J, 2012 [in press].
20. Reddy VY, Holmes D, Doshi SK et al. Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with af (protect af) clinical trial and the continued access registry. Circulation, 2011; 123: 417-424.
21. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
22. Sumary of produkt characteristics Eliquis. Dostȩpne: http://www.ema.europa.eu/docs/pl-PL/document-library/EPAR-Product-Information/ human//002148/WC500107728.pdf
23. Charakterystyka produktu leczniczego Xarelto. Dostȩpne: http://leki.urpl.gov.pl/files/Xarelto.pdf
24. Charakterystyka produktu leczniczego Pradaxa. Dostȩpne: http://leki.urpl.gov.pl/files/Pradaxa-110.pdf
25. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
26. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
27. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med, 2011; 365: 2039-2040.
28. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost, 2010; 103: 1116-1127.
29. Mani H, Hesse C, Stratmann G et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost, 2011; 106: 156-164.
30. Hillarp A, Baghaei F, Fagerberg Blixter I et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost, 2011; 9: 133-139.
31. Ansell J. New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation. Circulation, 2012; 125: 165-170.
32. Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation, 2012; 125: 159-164.
33. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 2011; 124: 1573-1579.
34. DeLoughery TG. Practical aspects of the oral new anticoagulants. Am J Hematol, 2011; 86: 586-590.
35. Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol, 2010; 9: 1157-1163.
36. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation, 2011; 123: 131-136.
37. You JJ, Singer DE, Howard PA et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis. 9th Ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141: e531S-575S.
38. Wann LS, Curtis AB, January CT et al. 2011 accf/aha/hrs focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol, 2011; 57: 223-242.
39. Hart RG, Pearce LA, Rothbart RM et al. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol, 2000; 35: 183-187.
40. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med, 2012; 366: 864-866.
41. Tendera M, Syzdol M, Parma Z. Aristotle re-lys on the rocket. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J, 2012; 19: 4-10.